Fundraising Fox
/Companies
Sign in

Alto Neuroscience

NYSE: ANRO

Mountain View, US · Founded 2019 · Delaware corporation · 15 known investors

Find your way into Alto Neuroscience

Each arrow is one introduction. Sign up to fill in the first one.

2,665 people can intro you to Amit

Ask Paul Kwan to introduce you to Amit Etkin

You →Paul · together at Stanford University →Amit

Sign up to find every way you can get introduced to Alto Neuroscience

  • Your email: who you already know at Alto Neuroscience, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Alto Neuroscience team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.

BiotechDigital HealthMental Health

Founders & leadership

Alto Neuroscience was founded in 2019 by Amit Etkin.

AEAmit Etkin
Amit EtkinFounder and CEOAmit Etkin is founder and CEO of Alto Neuroscience, a clinical-stage biopharmaceutical company using biomarkers to develop precision treatments for psychiatric conditions. A psychiatrist and neuroscientist, he joined the Stanford faculty in 2010 as a tenured professor, earned his PhD under Eric Kandel, and received the NIH Director's Pioneer Award.
ASAdam Savitz
Adam SavitzChief Medical Officer
MHMichael Hanley
Michael HanleyExecutive
NSNicholas Smith
Nicholas SmithChief Financial Officer and Chief Business Officer
AW
Aaron WeaverNamed on SEC filing
PY
Po Yu (Jeff) ChenNamed on SEC filing
CD
Chris DimitropoulosNamed on SEC filing

Board

GYGwill York
Gwill YorkBoard director
CNChristopher Nixon Cox
Christopher Nixon CoxBoard directorPartner at InVivium Capital
MLMichael Liang
Michael LiangBoard directorManaging Partner at InVivium Capital
HMHusseini Manji
Husseini ManjiBoard director
RSRaymond Sanchez
Raymond SanchezBoard director

Investors · 15

Alpha Wave Globallisted by Alpha Wave GlobalMiami

How we know: Alpha Wave Global's portfolio page · Not right? Tell us

InVivium Capitallisted by InVivium CapitalChicago
K2 HealthVentureslisted by K2 HealthVenturesBoston · $10M – $100M

How we know: K2 HealthVentures's portfolio page · Not right? Tell us

Korify Capitallisted by Korify Capital

How we know: Korify Capital's portfolio page · Not right? Tell us

Nat Turnerlisted by Nat TurnerNew York City

How we know: Nat Turner's portfolio page · Not right? Tell us

Valor Equity Partnerslisted by Valor Equity PartnersChicago

How we know: Valor Equity Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

What If Ventureslisted by What If VenturesFriscovia Stephen Hays · inferred

How we know: What If Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Windham Capital Partnerslisted by Windham Capital PartnersNew York · $1M – $5M
Baird CapitalreportedChicago

How we know: a partner's Signal profile · Not right? Tell us

BiovergereportedSan Francisco

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Gaorong VenturesreportedGeorge Town, Grand Cayman

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

Mana VenturesreportedEstero

How we know: the VCSheet dataset · Not right? Tell us

Presight CapitalreportedSliema · $500K – $20M

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$193.9M disclosed across 5 of 6 rounds · 2019–2026

▶$50MraisedOct 2025 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Adam SavitzExecutive Officer
  • Amit EtkinExecutive Officer, Director
  • Nicholas C. SmithExecutive Officer
  • Gwill YorkDirector
  • Husseini ManjiDirector
  • Christopher Nixon CoxDirector
  • Raymond SanchezDirector
  • Andrew DreyfusDirector
  • Michael HanleyExecutive Officer
Offering amount
$50M
Amount sold
$50M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$45MraisedNov 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael LiangDirector
  • Adam SavitzExecutive Officer
  • Christopher Nixon CoxDirector
  • Po Yu (Jeff) ChenDirector
  • Andrew DreyfusDirector
  • Amit EtkinExecutive Officer, Director
  • Aaron WeaverDirector
  • Chris DimitropoulosDirector
  • Nicholas SmithExecutive Officer
  • Gwill YorkDirector
Offering amount
$45M
Amount sold
$45M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$31.9MraisedNov 2023 · 19 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew DreyfusDirector
  • Michael LiangDirector
  • Aaron WeaverDirector
  • Christopher Nixon CoxDirector
  • Adam SavitzExecutive Officer
  • Nicholas SmithExecutive Officer
  • Gwill YorkDirector
  • Po Yu (Jeff) ChenDirector
  • Chris DimitropoulosDirector
  • Amit EtkinExecutive Officer, Director
Offering amount
$31.9M
Amount sold
$31.9M
First sale
May 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$59.3MraisedNov 2023 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Po Yu (Jeff) ChenDirector
  • Aaron WeaverDirector
  • Gwill YorkDirector
  • Amit EtkinExecutive Officer, Director
  • Chris DimitropoulosDirector
  • Michael LiangDirector
  • Adam SavitzExecutive Officer
  • Christopher Nixon CoxDirector
  • Andrew DreyfusDirector
  • Nicholas SmithExecutive Officer
Offering amount
$59.3M
Amount sold
$59.3M
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.7MraisedNov 2023 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Chris DimitropoulosDirector
  • Christopher Nixon CoxDirector
  • Michael LiangDirector
  • Aaron WeaverDirector
  • Andrew DreyfusDirector
  • Nicholas SmithExecutive Officer
  • Gwill YorkDirector
  • Adam SavitzExecutive Officer
  • Po Yu (Jeff) ChenDirector
  • Amit EtkinExecutive Officer, Director
Offering amount
$7.7M
Amount sold
$7.7M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$409.7Mvaluation at IPOFeb 2024 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 3

Altos LabsAltos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Alto Neuroscience.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$3.2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Alto Neuroscience do?
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates. Its initial focus areas include major depressive disorder, bipolar depression, and schizophrenia.
Who founded Alto Neuroscience?
Alto Neuroscience was founded by Amit Etkin in 2019.
Who are Alto Neuroscience's investors?
Alto Neuroscience's investors include Able Partners, Alpha Wave Global, InVivium Capital, K2 HealthVentures, Korify Capital, Nat Turner, Valor Equity Partners, Vivo Capital and 7 more.
How much funding has Alto Neuroscience raised?
Alto Neuroscience has disclosed $193.9M raised across 5 of its 6 known rounds.
Where is Alto Neuroscience headquartered?
Alto Neuroscience is headquartered in Mountain View, US.